Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $35.00 for the company and are forecasting that the company will post ($0.50) earnings per share for the current quarter, according to Zacks. Zacks has also given Kiniksa Pharmaceuticals an industry rank of 82 out of 255 based on the ratings given to related companies.
A number of analysts have commented on KNSA shares. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, September 11th. JMP Securities raised their target price on shares of Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the stock an “outperform” rating in a research note on Monday, September 17th.
KNSA stock traded up $1.41 during trading hours on Thursday, reaching $22.29. The stock had a trading volume of 47,566 shares, compared to its average volume of 156,141. Kiniksa Pharmaceuticals has a fifty-two week low of $13.04 and a fifty-two week high of $32.88.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Monday, August 6th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.53). As a group, equities research analysts predict that Kiniksa Pharmaceuticals will post -2.63 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Nexthera Capital LP acquired a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $680,000. Hillhouse Capital Management Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $99,529,000. Boxer Capital LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $20,346,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $115,000. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $52,050,000. Institutional investors own 34.91% of the company’s stock.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Further Reading: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.